C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers.
TL;DR: Metastatic urothelial and renal cell cancers continue to be the clinical trial focus of many novel agents and as knowledge accumulates, the ability to target these cancers will continue to increase.
Journal ArticleDOI
Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.
Howard I. Scher,Karim Fizazi,Fred Saad,Kim N. Chi,Mary-Ellen Taplin,Cora N. Sternberg,Andrew J. Armstrong,Mohammad Hirmand,David Forer,Johann S. de Bono +9 more
TL;DR: While CS pts had worse outcomes, ENZA was consistently superior to PBO regardless of on study CS use, and the inferior outcomes in CS pts may be due to unmeasured confounders or the biologic properties of CS use itself.
Journal ArticleDOI
Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma
Matteo Santoni,Alessandro Conti,Camillo Porta,Giuseppe Procopio,Cora N. Sternberg,Umberto Basso,Ugo De Giorgi,Sergio Bracarda,Mimma Rizzo,Cinzia Ortega,Francesco Massari,Roberto Iacovelli,Lisa Derosa,Cristina Masini,Michele Milella,Giuseppe Di Lorenzo,Francesco Atzori,Maria Pagano,Sebastiano Buti,Rocco De Vivo,Alessandra Mosca,Marta Rossi,Chiara Paglino,Elena Verzoni,Linda Cerbone,Giovanni Muzzonigro,Massimo Falconi,Rodolfo Montironi,Luciano Burattini,Daniele Santini,Stefano Cascinu +30 more
TL;DR: Patients with late relapsing renal cell carcinoma seem to present a characteristic pattern of metastatic spread without showing significant differences in terms of progression-free survival among sorafenib, sunitinib and pazopanib.
Journal ArticleDOI
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials
Giandomenico Roviello,Giandomenico Roviello,Sandra Sigala,Shahneen Sandhu,Alberto Bonetta,Maria Rosa Cappelletti,Laura Zanotti,Alberto Bottini,Cora N. Sternberg,Stephen B. Fox,Daniele Generali,Daniele Generali +11 more
TL;DR: This study confirmed the efficacy and safety of the novel androgen receptor pathway targeted agents in improving outcome of CRPC patients.
Journal ArticleDOI
Sequential use of targeted agents in the treatment of renal cell carcinoma
Thomas E. Hutson,Ronald M. Bukowski,C. Lance Cowey,Robert A. Figlin,Bernard Escudier,Cora N. Sternberg +5 more
TL;DR: Results from the only trial of sequenced targeted agents support the use of mammalian target of rapamycin inhibitors after resistance develops to vascular endothelial growth factor (VEGF) inhibitors.